A citation-based method for searching scientific literature


List of co-cited articles
48 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Impending epidemic: future projection of heart failure in Japan to the year 2055.
Yuji Okura, Mahmoud M Ramadan, Yukiko Ohno, Wataru Mitsuma, Komei Tanaka, Masahiro Ito, Keisuke Suzuki, Naohito Tanabe, Makoto Kodama, Yoshifusa Aizawa. Circ J 2008
192
10

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
35
10

Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure.
Chutima Talchai, Shouhong Xuan, Hua V Lin, Lori Sussel, Domenico Accili. Cell 2012
863
10

Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.
G A Nichols, T A Hillier, J R Erbey, J B Brown. Diabetes Care 2001
376
10



Gut hormone polyagonists for the treatment of type 2 diabetes.
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
64
10

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Michaël J B van Baar, Mark H H Kramer, Ewout J Hoorn, Jaap A Joles, Daniël H van Raalte. Nat Rev Nephrol 2017
151
10

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Sophie Hallakou-Bozec, Guillaume Vial, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, Anne-Laure Borel, Eric Fontaine, David E Moller. Diabetes Obes Metab 2021
22
10

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
Jens Juul Holst, Mette Marie Rosenkilde. J Clin Endocrinol Metab 2020
35
10

Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model.
Guillaume Vial, Marie-Agnès Chauvin, Nadia Bendridi, Annie Durand, Emmanuelle Meugnier, Anne-Marie Madec, Nathalie Bernoud-Hubac, Jean-Paul Pais de Barros, Éric Fontaine, Cécile Acquaviva,[...]. Diabetes 2015
74
10

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
315
10


Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans.
Thomas B Kjeldsen, František Hubálek, Claudia U Hjørringgaard, Tina M Tagmose, Erica Nishimura, Carsten E Stidsen, Trine Porsgaard, Christian Fledelius, Hanne H F Refsgaard, Sanne Gram-Nielsen,[...]. J Med Chem 2021
13
10

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
799
10

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
139
10

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
154
10


Diabetes mellitus--advances and challenges in human β-cell proliferation.
Peng Wang, Nathalie M Fiaschi-Taesch, Rupangi C Vasavada, Donald K Scott, Adolfo García-Ocaña, Andrew F Stewart. Nat Rev Endocrinol 2015
126
10

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
73
10

Semaglutide lowers body weight in rodents via distributed neural pathways.
Sanaz Gabery, Casper G Salinas, Sarah J Paulsen, Jonas Ahnfelt-Rønne, Tomas Alanentalo, Arian F Baquero, Stephen T Buckley, Erzsébet Farkas, Csaba Fekete, Klaus S Frederiksen,[...]. JCI Insight 2020
93
10


Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow.
Elisa P Jensen, Steen S Poulsen, Hannelouise Kissow, Niels-Henrik Holstein-Rathlou, Carolyn F Deacon, Boye L Jensen, Jens J Holst, Charlotte M Sorensen. Am J Physiol Renal Physiol 2015
72
10

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
197
10

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
73
10

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
167
10

Heart failure prevalence, incidence, and mortality in the elderly with diabetes.
Alain G Bertoni, W Gregory Hundley, Mark W Massing, Denise E Bonds, Gregory L Burke, David C Goff. Diabetes Care 2004
362
10

Augmentation of hepatic glucose uptake by a positive glucose gradient between hepatoportal and central nervous systems.
M Matsuhisa, T Morishima, I Nakahara, T Tomita, Y Shiba, M Kubota, M Wada, T Kanda, M Kubota, R Kawamori,[...]. Diabetes 1997
15
10

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A Karanikas, Vivian T Thieu. Lancet 2021
63
10


Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
723
10


The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
Meena Asmar, Ali Asmar, Lene Simonsen, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Bolette Hartmann, Flemming Dela, Jens Juul Holst, Jens Bülow. Diabetes 2017
60
10



Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes.
Christian Pennartz, Nina Schenker, Björn A Menge, Wolfgang E Schmidt, Michael A Nauck, Juris J Meier. Diabetes Care 2011
32
10

Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
Geisa Nogueira Salles, Michele Longoni Calió, Christian Hölscher, Cristina Pacheco-Soares, Marimelia Porcionatto, Anderson Oliveira Lobo. Neuropharmacology 2020
15
10

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
David S Mathiesen, Jonatan I Bagger, Natasha C Bergmann, Asger Lund, Mikkel B Christensen, Tina Vilsbøll, Filip K Knop. Int J Mol Sci 2019
23
10

As a matter of fat.
Rita T Brookheart, Carlos I Michel, Jean E Schaffer. Cell Metab 2009
185
10

GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release.
A H Sparre-Ulrich, M N Gabe, L S Gasbjerg, C B Christiansen, B Svendsen, B Hartmann, J J Holst, M M Rosenkilde. Biochem Pharmacol 2017
42
10


Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes.
Francesca Cinti, Ryotaro Bouchi, Ja Young Kim-Muller, Yoshiaki Ohmura, P R Sandoval, Matilde Masini, Lorella Marselli, Mara Suleiman, Lloyd E Ratner, Piero Marchetti,[...]. J Clin Endocrinol Metab 2016
290
10

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
273
10

Incretin hormones: Their role in health and disease.
Michael A Nauck, Juris J Meier. Diabetes Obes Metab 2018
229
10

Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.
Megumi Inoue, Masanari Shiramoto, Tomonori Oura, Risa Nasu, Masako Nakano, Masakazu Takeuchi. Diabetes Ther 2019
5
20

β-cell dedifferentiation in diabetes is important, but what is it?
Gordon C Weir, Cristina Aguayo-Mazzucato, Susan Bonner-Weir. Islets 2013
78
10


Sodium challenge does not support an acute gastrointestinal-renal natriuretic signaling axis in humans.
Richard A Preston, David Afshartous, Leonard R Forte, Rolando Rodco, Alberto B Alonso, Dyal Garg, Leopoldo Raij. Kidney Int 2012
18
10


A review of phenformin, metformin, and imeglimin.
Raghunandan Yendapally, Donald Sikazwe, Subin S Kim, Sushma Ramsinghani, Rheaclare Fraser-Spears, Amy P Witte, Brittany La-Viola. Drug Dev Res 2020
17
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.